Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals is a biopharmaceutical company dedicated to creating new categories in eye care and beyond. They focus on serving patient needs through innovative treatments, with a culture driven by commitment, empowerment, and teamwork. Their mission is to revolutionize treatment for patients with unmet needs by developing therapies that target root causes of diseases, such as Demodex blepharitis, Lyme disease, and ocular rosacea. They have FDA-approved therapies like XDEMVY® for Demodex blepharitis and are advancing a robust pipeline of investigational treatments for other significant unmet patient needs.
Industries
Nr. of Employees
medium (51-250)
Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road, Ste 160, Irvine, CA 92618
Patents
Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US-12257263-B2
View DetailsIsoxazoline parasiticide formulations and methods for treating blepharitis
US-12171750-B2
View DetailsOphthalmic compositions for treating ocular Demodex using lotilaner formulations
US-11752137-B2
View Details
Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US-12257263-B2
View DetailsIsoxazoline parasiticide formulations and methods for treating blepharitis
US-12171750-B2
View DetailsOphthalmic compositions for treating ocular Demodex using lotilaner formulations
US-11752137-B2
View DetailsProducts
Preservative-containing topical ophthalmic antiparasitic solution (0.25%) — marketed
A preservative-containing topical ophthalmic solution containing an antiparasitic small molecule approved for treatment of eyelid infestation–associated blepharitis; includes prescribing and safety information.
Sterile topical ophthalmic gel formulation (investigational) — ocular rosacea
Investigational sterile topical ophthalmic gel formulation of an antiparasitic agent in development for periorbital and eyelid application to treat ocular rosacea; program planned to enter Phase 2.
Oral systemic antiparasitic formulation (investigational) — vector-targeting prophylactic
Investigational oral systemic small-molecule formulation being developed as a non‑vaccine prophylactic intended to provide on‑demand systemic levels to kill infected vectors prior to pathogen transmission; currently evaluated in a Phase 2a trial.
Preservative-containing topical ophthalmic antiparasitic solution (0.25%) — marketed
A preservative-containing topical ophthalmic solution containing an antiparasitic small molecule approved for treatment of eyelid infestation–associated blepharitis; includes prescribing and safety information.
Sterile topical ophthalmic gel formulation (investigational) — ocular rosacea
Investigational sterile topical ophthalmic gel formulation of an antiparasitic agent in development for periorbital and eyelid application to treat ocular rosacea; program planned to enter Phase 2.
Oral systemic antiparasitic formulation (investigational) — vector-targeting prophylactic
Investigational oral systemic small-molecule formulation being developed as a non‑vaccine prophylactic intended to provide on‑demand systemic levels to kill infected vectors prior to pathogen transmission; currently evaluated in a Phase 2a trial.
Services
End-to-end clinical development services across preclinical, Phase 1–3 clinical trials for ocular and infectious-disease candidates.
Preparation and management of regulatory filings and approval strategies for U.S. and international markets.
Medical communications, publications support, and education for clinicians and investigators.
Management and public disclosure of patent portfolios covering product compositions and methods of use.
Commercial planning, market access and launch operations for prescription ophthalmic products.
End-to-end clinical development services across preclinical, Phase 1–3 clinical trials for ocular and infectious-disease candidates.
Preparation and management of regulatory filings and approval strategies for U.S. and international markets.
Medical communications, publications support, and education for clinicians and investigators.
Management and public disclosure of patent portfolios covering product compositions and methods of use.
Commercial planning, market access and launch operations for prescription ophthalmic products.
Expertise Areas
- Ophthalmic therapeutics development
- Clinical trial management and execution (including Phase 1 and Phase 2a progression)
- Regulatory strategy and product approval
- Chemistry, Manufacturing and Controls (CMC) and drug‑delivery systems
Key Technologies
- Topical ophthalmic small-molecule formulations (solutions and sterile gels)
- Oral systemic small-molecule formulations for prophylaxis
- Drug-delivery technologies (sustained-release and multidose container systems)
- Preclinical-to-clinical translational research
News & Updates
Tarsus to participate in upcoming investor conferences on May 8, 2025.
Tarsus reports financial results for Q1 2025 and recent achievements.
Tarsus' pipeline is anchored by lotilaner, the active ingredient in XDEMVY®, which has the potential to treat multiple diseases by targeting their root causes.
First and only FDA-approved treatment for Demodex blepharitis.
Tarsus to participate in upcoming investor conferences on May 8, 2025.
Tarsus reports financial results for Q1 2025 and recent achievements.
Tarsus' pipeline is anchored by lotilaner, the active ingredient in XDEMVY®, which has the potential to treat multiple diseases by targeting their root causes.
First and only FDA-approved treatment for Demodex blepharitis.